Drug
Ixabepilone clinical trials
Also written BMS-247550, Ixempra and Azaepothilone B.
- studies test it
- 102
- open now
- 0
- in phase 3
- 6
- first study started
- 1999
How studies write it
Studies that test it under each name
Studies by the year they started
101 studies that test it; most in 2008 (18)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 3 |
| 2001 | 13 |
| 2002 | 6 |
| 2003 | 7 |
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 7 |
| 2007 | 6 |
| 2008 | 18 |
| 2009 | 16 |
| 2010 | 6 |
| 2011 | 3 |
| 2013 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 38
- Phase 2
- 67
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 68
National Cancer Institute (NCI) (28) · R-Pharm (28) · Memorial Sloan Kettering Cancer Center (5) · SCRI Development Innovations, LLC (4) · Bristol-Myers Squibb (3) · SWOG Cancer Research Network (3) · Montefiore Medical Center (2) · University of Texas Southwestern Medical Center (2)
Often tested with
Tested in the same studies.
Capecitabine (6) · Carboplatin (5) · Bevacizumab (3) · Paclitaxel (3) · Cetuximab (3) · Trastuzumab (3) · Temsirolimus (2) · Albumin-Bound Paclitaxel (2)
Studies
Open first, then newest update. How each study uses ixabepilone is read from its arms, and is right about nine times in ten.
Testing it · 102
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01375829Written as Ixabepilone
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00977574Written as Ixabepilone
- Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerCompletedPhase 3National Cancer Institute (NCI)NCT00785291Written as Ixabepilone
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic TherapyActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT00877500Written as Ixabepilone
- Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.TerminatedPhase 2Allarity TherapeuticsNCT04796324Written as Ixabepilone Injection
- Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerWithdrawnPhase 1/2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01349088Written as Ixabepilone
- BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous TherapyCompletedPhase 1National Cancer Institute (NCI)NCT00020371Written as BMS-247550
- Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerCompletedPhase 3UNICANCERNCT00630032Written as ixabepilone
- Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast CancerTerminatedPhase 1/2University of Medicine and Dentistry of New JerseyNCT00765765Written as ixabepilone
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast CancerCompletedPhase 2Eisai Inc.NCT00879086Written as Ixabepilone
- Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)CompletedPhase 2The Methodist Hospital Research InstituteNCT01446016Written as Ixabepilone
- Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate CancerCompletedPhase 2Brown UniversityNCT00828308Written as Ixabepilone
- Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast CancerCompletedPhase 2SCRI Development Innovations, LLCNCT00866905Written as Ixabepilone
- Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedPhase 3R-PharmNCT00080301Written as Ixabepilone + Capecitabine
- Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.CompletedPhase 1R-PharmNCT00162136Written as Ixabepilone
- Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced CancerCompletedPhase 1R-PharmNCT00207090Written as ixabepilone
- Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedPhase 3R-PharmNCT00082433Written as Ixabepilone + Capecitabine
- A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung CancerCompletedPhase 2R-PharmNCT00723957Written as Ixabepilone, 32 mg/m^2
- Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric CancerCompletedPhase 2R-PharmNCT00983801Written as Ixabepilone
- Phase I Combination Ixabepilone + CisplatinCompletedPhase 1R-PharmNCT00832117Written as Ixabepilone
See all 102 studies that test ixabepilone →
Given in every arm · 8 — ixabepilone is usual care beside what is tested
- Evaluation of Weekly Ixabepilone With or Without Biweekly BevacizumabCompletedPhase 2Yale UniversityNCT03093155Written as Ixabepilone
- Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerCompletedPhase 2SCRI Development Innovations, LLCNCT00741988Written as Ixabepilone
- Neo-Adjuvant Study in Triple Negative Breast Cancer PatientsCompletedPhase 2The Methodist Hospital Research InstituteNCT01097642Written as Ixabepilone
- A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade GliomasCompletedPhase 1/2National Cancer Institute (NCI)NCT00045708Written as ixabepilone
- Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast CancerTerminatedPhase 3Mayo ClinicNCT00998738Written as Ixabepilone
- Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced CancersCompletedPhase 1Bristol-Myers SquibbNCT00798252Written as Ixabepilone
- BMS-247550 in Treating Patients With Metastatic Colorectal CancerTerminatedPhase 2University of Alabama at BirminghamNCT00033306Written as ixabepilone
- BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT00057850Written as ixabepilone
As the comparator · 2 — what is tested is compared with ixabepilone
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineCompletedPhase 3Nektar TherapeuticsNCT02915744Written as Ixabepilone
- A Study of LY2523355 in Participants With Breast CancerCompletedPhase 2Eli Lilly and CompanyNCT01416389Written as ixabepilone
Codes
What other systems call ixabepilone · ClinicalTrials.gg INT004356
- MeSH (NLM) C430592ixabepiloneConfirmed NLM, Wikidata
- UNII (FDA) K27005NP0AIXABEPILONEConfirmed FDA, NLM, Wikidata
- RxNorm 337523Confirmed FDA, Wikidata
- Wikidata Q11711607ixabepiloneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C37452IxabepiloneOne source FDA
- DrugBank DB04845One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C430592 | ixabepilone | Confirmed NLM, Wikidata |
| UNII (FDA) | K27005NP0A | IXABEPILONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 337523 | — | Confirmed FDA, Wikidata |
| Wikidata | Q11711607 | ixabepilone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C37452 | Ixabepilone | One source FDA |
| DrugBank | DB04845 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.